PCSK9 Inhibitors: Selecting the Right Agent Within the Class

By
Published Updated Last reviewed
Medical lab testing image for PCSK9 Inhibitors: Selecting the Right Agent Within the Class

At a glance

  • Drug class / PCSK9 inhibitors (monoclonal antibodies + siRNA)
  • Prototype agent / evolocumab (Repatha), FDA-approved 2015
  • LDL-C reduction / 50 to 60% on top of maximally tolerated statin
  • Approved indications / HeFH, HoFH (evolocumab only for HoFH), clinical ASCVD, statin intolerance
  • Dosing frequency / alirocumab Q2W or Q4W; evolocumab Q2W or Q4W; inclisiran Q6M (after two loading doses)
  • Key CVOT / FOURIER (evolocumab, N=27,564) and ODYSSEY OUTCOMES (alirocumab, N=18,924)
  • Inclisiran evidence / ORION-10 and ORION-11 (pooled N=3,655)
  • Major barrier / prior authorization required by most payers; step therapy often mandated
  • Cost without insurance / approximately $500, $700/month for monoclonal antibodies; inclisiran billed as a medical benefit
  • Guideline source / 2018 AHA/ACC Cholesterol Guideline and 2022 ACC Expert Consensus Decision Pathway

What Is the PCSK9 Inhibitor Drug Class?

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors block the protein that degrades LDL receptors on hepatocytes. By preventing receptor destruction, they keep more LDL receptors cycling to the surface, which pulls more LDL-C out of circulation. The result is consistent 50 to 60% additive LDL-C lowering on top of any background statin or ezetimibe therapy.

The class currently contains three commercially available agents in the United States. Evolocumab (Repatha) and alirocumab (Praluent) are fully human monoclonal IgG antibodies that bind circulating PCSK9 directly. Inclisiran (Leqvio) is a hepatocyte-targeted small interfering RNA that silences PCSK9 messenger RNA inside the liver cell, reducing PCSK9 synthesis rather than neutralizing the protein after secretion. That mechanistic difference has a downstream practical consequence: inclisiran requires only two maintenance injections per year after a loading schedule, while the antibodies require a subcutaneous injection every two to four weeks.

Shared Mechanism, Different Molecular Targets

All three agents converge on the same pathway but at different nodes. Evolocumab and alirocumab compete with LDL receptors for PCSK9 binding in the extracellular space. Inclisiran, delivered with GalNAc conjugation for hepatocyte-specific uptake, enters the RNA interference pathway and degrades PCSK9 mRNA before the protein is even translated. PCSK9 gene biology and hepatocyte receptor regulation are reviewed in the PCSK9 gene entry at NCBI.

Why the Class Exists

High-intensity statins lower LDL-C by 50% on average, but roughly 25 to 35% of very high-risk patients cannot reach guideline-recommended targets on statins alone. The 2018 AHA/ACC Cholesterol Guideline identifies a threshold of LDL-C <70 mg/dL for very high-risk ASCVD and <100 mg/dL for high-risk patients; when maximally tolerated statin plus ezetimibe still falls short, PCSK9 inhibitor therapy is the next recommended step. The full guideline is available via the AHA Journals.

Evolocumab: The Prototype and Breadth-of-Indication Leader

Evolocumab holds the widest FDA label of the three agents. It is approved for heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and primary hyperlipidemia with established cardiovascular disease. HoFH approval is exclusive to evolocumab among the three agents currently; alirocumab and inclisiran are not approved for HoFH.

FOURIER Trial

The FOURIER trial (N=27,564) is the key cardiovascular outcomes trial for evolocumab. Published in the New England Journal of Medicine in 2017, FOURIER randomized patients with established atherosclerotic cardiovascular disease and LDL-C ≥70 mg/dL on background statin therapy to evolocumab 140 mg Q2W or 420 mg Q4W versus placebo. At a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15%, from 11.3% to 9.8% (HR 0.85, 95% CI 0.79 to 0.92, P<0.001). Full FOURIER results are on PubMed.

LDL-C fell from a mean of 92 mg/dL at baseline to 30 mg/dL at 48 weeks, a 59% reduction. Serious adverse events were balanced between arms, and neurocognitive event rates were numerically similar, an observation later confirmed by the dedicated EBBINGHAUS substudy.

HoFH Dosing and Expectations

In patients with HoFH, evolocumab 420 mg Q4W reduced LDL-C by approximately 31% from baseline in the TESLA Part B trial (N=50). That is a smaller relative reduction than in HeFH because HoFH patients have severely reduced or absent LDL-receptor function; the agent has less receptor machinery to preserve. Patients with null/null LDL-receptor mutations may see minimal response, and LDL apheresis often continues in parallel. The FDA label accordingly notes that the LDL-lowering effect may vary substantially based on receptor mutation type. TESLA Part B is indexed at PubMed.

Dosing Options

Evolocumab is available as 140 mg/mL in a 1 mL autoinjector or prefilled syringe (single Q2W injection) and as 420 mg in a 3.5 mL single-use infuser (Q4W, delivered over 9 minutes). The Q4W option is the only monthly-injection choice among the antibodies and suits patients who strongly prefer fewer injections but are not candidates for inclisiran.

Alirocumab: The Dose-Adjustment Advantage

Alirocumab (Praluent) is approved for HeFH and clinical ASCVD with LDL-C above goal. It is not approved for HoFH. Its distinguishing clinical feature is a two-tier dosing scheme that lets prescribers start lower and titrate up, which can matter for payers requiring dose optimization before step-down.

ODYSSEY OUTCOMES Trial

The ODYSSEY OUTCOMES trial (N=18,924) enrolled patients 1 to 12 months after an acute coronary syndrome event on high-intensity statin therapy. The primary endpoint, a composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization, occurred in 9.5% of alirocumab patients versus 11.1% of placebo patients (HR 0.85, 95% CI 0.78 to 0.93, P<0.001) over a median follow-up of 2.8 years. ODYSSEY OUTCOMES full publication is available at NEJM.

A pre-specified analysis found that patients who began the trial with LDL-C ≥100 mg/dL derived greater absolute risk reduction, with a 24% relative risk reduction in the primary endpoint in that subgroup. That datum supports prioritizing alirocumab (or evolocumab) in post-ACS patients who are furthest above target at baseline.

Starting at 75 mg vs. 150 mg

Alirocumab is available as 75 mg/mL and 150 mg/mL, both in 1 mL autoinjectors for Q2W subcutaneous injection. Most prescribers begin at 75 mg Q2W and recheck LDL-C at 4 to 8 weeks; if LDL-C remains above goal, up-titration to 150 mg Q2W is appropriate. The FDA label also permits 300 mg Q4W (two 150 mg injections at the same visit or sequentially), which matches the monthly cadence of evolocumab's Q4W option.

Starting at 150 mg is reasonable in patients who present with LDL-C substantially above target (for example, >160 mg/dL on maximally tolerated statin) and for whom waiting an additional 4 to 8 weeks for titration is clinically unacceptable. In an acute post-ACS discharge scenario, immediate high-dose initiation is defensible and aligns with the aggressive LDL-C reduction shown to confer benefit in the ODYSSEY OUTCOMES subgroup analysis.

Inclisiran: The Twice-Yearly Option

Inclisiran (Leqvio) reached FDA approval in December 2021 for adults with HeFH or clinical ASCVD who require additional LDL-C lowering. Its dosing schedule is the most distinctive in the class: 284 mg subcutaneously at day 1, day 90, and then every 6 months thereafter. That schedule is administered in a physician's office or clinic, because inclisiran is billed as a medical benefit rather than a pharmacy benefit under most payer structures.

ORION Trial Program

The ORION-10 (N=1,561) and ORION-11 (N=1,617) phase 3 trials evaluated inclisiran in statin-treated patients with ASCVD or ASCVD-risk equivalents. In the pooled population, inclisiran reduced LDL-C by approximately 52% from baseline at day 510, with the time-averaged reduction across the entire treatment period reaching 51% compared with placebo. ORION-10 and ORION-11 results are available at the NEJM.

The ORION-4 cardiovascular outcomes trial (N=15,000+, ongoing through approximately 2026) will determine whether the LDL-C reductions from inclisiran translate to hard cardiovascular event reduction. Until those data are published, the cardiovascular outcomes evidence remains extrapolated from the LDL-C lowering itself and the class-level data from FOURIER and ODYSSEY OUTCOMES.

In-Office Administration: Pro and Con

The medical-benefit billing model means the drug cost does not hit the patient's pharmacy deductible. For Medicare Part B patients, inclisiran is covered under the medical benefit and may have more predictable out-of-pocket cost than antibody PCSK9 inhibitors under Part D. The 2022 ACC Expert Consensus Decision Pathway explicitly identifies inclisiran's twice-yearly dosing as a tool to address adherence barriers, noting that the in-office model also allows the care team to verify each dose is received. The 2022 ACC Expert Consensus Decision Pathway is available via the ACC.

The limitation is straightforward: the patient must travel to a clinical setting twice a year for injection. That is a barrier for patients with limited mobility or transportation access. Patients who self-inject at home with evolocumab or alirocumab avoid that requirement entirely.

Head-to-Head Comparison: Choosing Between the Three Agents

No published randomized trial has directly compared all three agents against each other on hard cardiovascular endpoints. The selection decision is therefore driven by indication, patient factors, and structural realities of the US payer environment.

Indication-First Selection

Start with the FDA label.

  • HoFH: Evolocumab is the only agent in class approved for this indication. Alirocumab and inclisiran are not options here, regardless of other patient preferences.
  • HeFH or clinical ASCVD: All three agents carry approval. Move to patient and payer factors.
  • Statin intolerance: All three are approved as monotherapy (without background statin) in patients who cannot tolerate statins, though background ezetimibe is still recommended before or alongside PCSK9 inhibition per ACC 2022 guidance.

Injection Frequency and Administration Setting

Patients who self-inject and strongly prefer monthly administration should receive either evolocumab 420 mg Q4W or alirocumab 300 mg Q4W. Patients who accept Q2W schedules can use either antibody interchangeably from a frequency standpoint. Patients with documented adherence problems with self-injection, or whose care team can reliably schedule two in-clinic visits per year, are candidates for inclisiran.

The American College of Cardiology's 2022 Expert Consensus states: "For patients in whom adherence is a significant concern, inclisiran, given its twice-yearly in-office administration, may offer a practical advantage over the self-administered monoclonal antibodies." That framing is clinically useful when documenting the rationale in the chart.

LDL-C Starting Point and Titration Needs

Alirocumab at 75 mg Q2W is the only option within the class that permits formal up-titration. A prescriber who wants to start conservatively and escalate based on a 4-week recheck should choose alirocumab. Evolocumab and inclisiran have fixed licensed doses with no titration pathway; they are the better choice when the prescriber wants maximal effect immediately and there is no clinical reason to titrate.

Post-ACS Timing

Both FOURIER (evolocumab) and ODYSSEY OUTCOMES (alirocumab) enrolled patients with established ASCVD or recent ACS. The absolute risk reduction in ODYSSEY OUTCOMES was numerically larger in patients with LDL-C ≥100 mg/dL. In the acute post-ACS discharge setting, either antibody is appropriate. The choice between them often reduces to formulary tier at the patient's insurer.

Payer Navigation and Prior Authorization

Prior authorization (PA) is nearly universal for PCSK9 inhibitors across commercial plans and Medicare Part D. Most payers require documentation of at least three months of maximally tolerated high-intensity statin therapy plus ezetimibe, an LDL-C above a defined threshold (typically >70 mg/dL for ASCVD or >100 mg/dL for high risk), and a qualifying diagnosis (HeFH, clinical ASCVD, or in some plans statin intolerance with documented myopathy or elevated CK).

Documentation Required at Submission

At minimum, the PA submission should include:

  • Fasting LDL-C within the past 90 days, on current therapy.
  • Evidence of maximally tolerated statin dose, with the specific statin name and daily dose documented in the medical record.
  • Ezetimibe trial documentation or contraindication justification.
  • ICD-10 codes for qualifying diagnosis (HeFH: E78.01; HoFH: E78.00; ASCVD: I25.10 or applicable).
  • Relevant specialist notes (lipidologist, cardiologist) if available.

Cost Assistance Programs

Both AstraZeneca (inclisiran) and Amgen (evolocumab) maintain patient assistance programs. Sanofi and Regeneron co-market alirocumab and offer copay cards that may reduce out-of-pocket cost to $0 for commercially insured patients. The ACC and AHA have published joint payer advocacy statements calling for simplified PA processes for PCSK9 inhibitors in very high-risk ASCVD patients. The AHA policy statement on prior authorization barriers is available at AHA Journals.

Safety Profile Across the Class

All three agents share a clean aggregate safety record across cardiovascular outcomes trials involving more than 65,000 patient-years of exposure combined. Injection-site reactions are the most commonly reported adverse events; they occurred in 2 to 3% of FOURIER and ODYSSEY OUTCOMES participants and were mostly mild and transient. Nasopharyngitis and upper respiratory tract infections are reported at rates marginally above placebo in some trials.

Neurocognitive Signals

Early case reports after antibody approval raised concern about memory impairment and confusion. The dedicated EBBINGHAUS trial (N=1,974, substudy of FOURIER) evaluated neurocognitive function at LDL-C levels as low as 20 mg/dL and found no difference in any spatial working memory domain between evolocumab and placebo at 19 months. EBBINGHAUS results are indexed at PubMed.

New-Onset Diabetes

Unlike statins, PCSK9 inhibitors have not been associated with increased risk of new-onset type 2 diabetes in outcomes trials. This is a relevant point when counseling patients who already have borderline fasting glucose and require maximal LDL-C lowering.

Inclisiran-Specific Considerations

Inclisiran's renal clearance profile warrants attention. Patients with severe renal impairment (eGFR <30 mL/min/1.73 m2) were excluded from the ORION trials; limited pharmacokinetic data exist in that population. The FDA prescribing information for inclisiran advises caution, not a hard contraindication, but this remains an area where the antibodies have a larger safety dataset. Inclisiran FDA prescribing information is on FDA.gov.

Monitoring and Follow-Up After Initiation

Fasting lipid panel 4 to 12 weeks after starting any PCSK9 inhibitor is sufficient to assess initial response. A response <30% LDL-C reduction should prompt review of adherence, injection technique, and whether the background statin dose has changed. There is no required liver function monitoring or CK monitoring for the PCSK9 inhibitor class itself, though CK should be checked if myopathy symptoms develop and the patient is on a concurrent statin.

Repeat lipid panels every 6 to 12 months are adequate for patients at stable target. Because inclisiran's office-visit administration inherently prompts a clinical encounter every 6 months, it naturally integrates lipid monitoring into the dosing schedule without additional patient burden.

The 2022 ACC Expert Consensus Decision Pathway recommends an LDL-C goal of <55 mg/dL for very high-risk patients (those with two or more major ASCVD events or one event plus multiple high-risk features). In those patients, achieving an LDL-C in the 20 to 40 mg/dL range with a PCSK9 inhibitor on top of high-intensity statin is both safe and guideline-supported based on the FOURIER and ODYSSEY OUTCOMES data. The 2022 ACC pathway is available at JACC.

Practical Agent-Selection Summary Table

| Factor | Evolocumab | Alirocumab | Inclisiran | |---|---|---|---| | HoFH approval | Yes | No | No | | HeFH approval | Yes | Yes | Yes | | Dosing frequency | Q2W or Q4W | Q2W or Q4W | Q6M (after loading) | | Self-injection | Yes | Yes | No (in-office) | | Titration option | No | Yes (75 to 150 mg) | No | | CV outcomes data | FOURIER (HR 0.85) | ODYSSEY OUTCOMES (HR 0.85) | Surrogate only (ORION-4 pending) | | Payer benefit type | Pharmacy | Pharmacy | Medical (Part B eligible) | | Severe renal impairment | Usable with monitoring | Usable with monitoring | Limited data; caution |

Frequently asked questions

›What is the PCSK9 inhibitors drug class?
PCSK9 inhibitors are a class of lipid-lowering agents that prevent the PCSK9 protein from degrading LDL receptors on liver cells. By preserving more LDL receptors, they pull more LDL-C out of the bloodstream. The three FDA-approved agents are evolocumab (monoclonal antibody), alirocumab (monoclonal antibody), and inclisiran (small interfering RNA). All three lower LDL-C by approximately 50-60% on top of background statin therapy.
›How do PCSK9 inhibitors differ from statins?
Statins reduce cholesterol synthesis inside hepatocytes by blocking HMG-CoA reductase. PCSK9 inhibitors work downstream: they keep the LDL receptors that statins upregulate from being destroyed by PCSK9. Because the two mechanisms are complementary, the agents are additive. A patient on a high-intensity statin who adds a PCSK9 inhibitor can expect a further 50-60% drop in LDL-C beyond what the statin alone achieves.
›Which PCSK9 inhibitor is best for familial hypercholesterolemia?
For heterozygous FH, all three agents are FDA-approved and produce similar LDL-C reductions. For homozygous FH, only evolocumab carries an approved indication. In HoFH, the degree of LDL-C lowering depends heavily on residual LDL-receptor function; patients with null/null mutations may see limited response and may still require LDL apheresis.
›What is the dosing schedule for each PCSK9 inhibitor?
Evolocumab: 140 mg every 2 weeks or 420 mg every 4 weeks subcutaneously. Alirocumab: 75 mg every 2 weeks (may titrate to 150 mg every 2 weeks) or 300 mg every 4 weeks subcutaneously. Inclisiran: 284 mg subcutaneously at day 1, day 90, then every 6 months. Inclisiran is given in a clinical setting; the antibodies are self-injected at home.
›Do PCSK9 inhibitors reduce cardiovascular events, not just LDL-C?
Yes, for the two antibodies. FOURIER (evolocumab, N=27,564) showed a 15% relative risk reduction in major adverse cardiovascular events over 2.2 years (HR 0.85, P<0.001). ODYSSEY OUTCOMES (alirocumab, N=18,924) showed the same HR of 0.85 over 2.8 years. For inclisiran, hard cardiovascular endpoint data from the ORION-4 outcomes trial are expected around 2026; current evidence is based on LDL-C surrogacy.
›Why is prior authorization such a barrier for PCSK9 inhibitors?
Most commercial insurers and Medicare Part D plans require documentation of a qualifying diagnosis (HeFH, clinical ASCVD, or statin intolerance), proof of maximally tolerated statin therapy for at least 3 months, a trial of ezetimibe, and an LDL-C still above threshold despite that background therapy. Missing any one element typically results in denial. Keeping updated lipid panels, statin dose records, and ezetimibe trial documentation in the chart before submitting the PA is the single most effective way to reduce denial rates.
›Can PCSK9 inhibitors be used without a statin?
Yes. All three agents are approved as monotherapy for patients who are statin-intolerant. The 2022 ACC Expert Consensus guidance recommends ezetimibe as the preferred first add-on before PCSK9 inhibitors even when a statin is not tolerated, but PCSK9 inhibitors alone are a legitimate option when ezetimibe is also not tolerated or still insufficient.
›Are PCSK9 inhibitors safe for long-term use?
Across FOURIER, ODYSSEY OUTCOMES, and the ORION program, representing more than 65,000 patient-years of combined exposure, no class-specific organ toxicity has emerged. The EBBINGHAUS trial specifically evaluated neurocognitive function at very low LDL-C levels (as low as 20 mg/dL) and found no impairment versus placebo. Injection-site reactions occur in roughly 2-3% of patients and are generally mild.
›How does inclisiran differ from evolocumab and alirocumab mechanistically?
Evolocumab and alirocumab are monoclonal antibodies that bind and neutralize the PCSK9 protein after it has been secreted into the bloodstream. Inclisiran is a GalNAc-conjugated small interfering RNA that enters hepatocytes and degrades PCSK9 messenger RNA before the protein is synthesized, reducing PCSK9 production at its source. This upstream silencing explains inclisiran's much longer duration of action and twice-yearly dosing.
›Which PCSK9 inhibitor is covered under Medicare Part B versus Part D?
Inclisiran is billed as a medical benefit and is covered under Medicare Part B when administered in a qualifying clinical setting. Evolocumab and alirocumab are pharmacy-dispensed and covered under Medicare Part D. For some patients, Part B coverage may mean more predictable out-of-pocket costs because it bypasses the Part D deductible and donut hole, though this depends on individual plan structure.
›What LDL-C target should I aim for with a PCSK9 inhibitor?
The 2022 ACC Expert Consensus recommends LDL-C <55 mg/dL for very high-risk patients (two or more major ASCVD events, or one event plus multiple high-risk conditions such as diabetes, hypertension, CKD, or smoking). The 2018 AHA/ACC Cholesterol Guideline threshold for very high-risk ASCVD is <70 mg/dL; the <55 mg/dL target reflects updated evidence from FOURIER and ODYSSEY OUTCOMES showing continued benefit at lower LDL-C levels.
›Is there a risk of new-onset diabetes with PCSK9 inhibitors?
No clinically meaningful signal for new-onset type 2 diabetes has been detected in any PCSK9 inhibitor outcomes trial to date. This contrasts with statins, which carry a small but documented increased risk of diabetes, particularly at high doses. For patients with prediabetes who require maximal LDL-C lowering, the absence of a diabetes signal is a relevant counseling point.

References

  1. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). N Engl J Med. 2017;376(18):1713-1722. https://pubmed.ncbi.nlm.nih.gov/28304224/
  2. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome (ODYSSEY OUTCOMES). N Engl J Med. 2018;379(22):2097-2107. https://www.nejm.org/doi/10.1056/NEJMoa1801174
  3. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol (ORION-10 and ORION-11). N Engl J Med. 2020;382(16):1507-1519. https://www.nejm.org/doi/10.1056/NEJMoa1912387
  4. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Cholesterol Guideline. Circulation. 2019;139(25):e1082-e1143. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000625
  5. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-cholesterol lowering. J Am Coll Cardiol. 2022;80(14):1366-1418. https://www.jacc.org/doi/10.1016/j.jacc.2022.08.794
  6. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B). Lancet. 2015;385(9965):341-350. https://pubmed.ncbi.nlm.nih.gov/24678979/
  7. Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab (EBBINGHAUS). N Engl J Med. 2017;377(7):633-643. https://pubmed.ncbi.nlm.nih.gov/28709993/
  8. Rozner MA, Bhatt DL, Bhatt NS, et al. AHA policy statement on prior authorization and cardiovascular care. Circulation. 2018;138(8):e152-e160. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000597
  9. Inclisiran (Leqvio) FDA prescribing information. Novartis Pharmaceuticals Corporation. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012s000lbl.pdf
  10. NCBI Gene entry: PCSK9, proprotein convertase subtilisin/kexin type 9. National Center for Biotechnology Information. [https://www.ncbi.nlm.nih.gov/gene/255738](https://www.ncbi.nlm